Abstract:Hintergrund Patienten, die wegen ihrer Erkrankung bzw. Therapie ein erhöhtes Risiko haben, unzureichend auf COVID-19-Impfungen anzusprechen, sind potenziell vulnerabel gegenüber schweren COVID-19-Verläufen. Ziel ist es, ihre Populationsgröße, klinischen Verläufe und Hospitalisierungskosten in Deutschland zu beurteilen. Methode Die retrospektive Kohortenstudie basiert auf Hochrechnungen einer repräsentativen Stichprobe von GKV-Abrechnungsdaten des Jahres 2020. Klinische COVID-19-Verläufe, Hospitalisierungskosten und -dauern werden zwischen der Gruppe mit erhöhtem Risiko für inadäquate Immunreaktion auf COVID-19-Impfungen (Risikogruppe) und der Gruppe ohne dieses Risiko verglichen. Ergebnisse Es gibt ca. 1,82 Mio. GKV-Versicherte in der Risikogruppe, von denen schätzungsweise 240 000 Versicherte keine humorale Immunantwort nach 3 COVID-19-Impfungen bilden. Die Risikogruppe zeigt im Vergleich zur Gruppe ohne Risiko höhere Anteile mit COVID-19 (Relatives Risiko [RR] 1,21; 95 %-Konfidenzintervall [95 %-KI] 1,20–1,23), Hospitalisierungen wegen COVID-19 (RR 3,40; 95 %-KI 3,33–3,48), Hospitalisierungen wegen COVID-19 mit intensivmedizinischer Behandlung (RR 1,36; 95 %-KI 1,30–1,42) und Mortalität (RR 5,14; 95 %-KI 4,97–5,33). Zudem sind Hospitalisierungen in der Risikogruppe durchschnittlich 18 % länger (15,36 Tage vs. 13,00 Tage) und 19 % teurer (12 371 € vs. 10 410 €). Die erwarteten Hospitalisierungskosten in der Risikogruppe betragen das Vierfache der Gruppe ohne Risiko (4115 € vs. 1017 €). Diskussion Die Risikogruppe ist vulnerabel gegenüber COVID-19 und beansprucht zusätzliche Ressourcen im deutschen stationären Sektor. Hieraus resultiert ein Bedarf an weiteren Schutzmöglichkeiten. Weitere Studien sind notwendig, um den Einfluss verschiedener Virusvarianten, aktiver/passiver Immunisierungen und Therapien auf die klinischen COVID-19-Verläufe und deren Kosten zu bewerten. Background Patients at increased risk of inadequate immune response to COVID-19 vaccinations due to their underlying disease or therapy are potentially vulnerable to severe COVID-19 courses. The aim is to assess the population size, clinical courses and hospitalization costs of these patients in Germany. Methods This retrospective cohort study is based on extrapolations of a representative sample of statutory health insurance (SHI) claims data from 2020. Clinical COVID-19 courses, hospitalization costs and durations are compared between the insured group at increased risk for inadequate immune response to COVID-19 vaccinations (risk group) and the insured group without this risk. Results There are approximately 1.82 million SHI-insured individuals in the risk group, of whom an estimated 240 000 insured individuals do not develop a humoral immune response after 3 COVID-19 vaccinations. The risk group shows higher proportions with COVID-19 (relative risk [RR] 1.21; 95 % confidence interval [95 % CI] 1.20–1.23), hospitalizations for COVID-19 (RR 3.40; 95 % CI 3.33–3.48), hospitalizations for COVID-19 with intensive care treatment (RR 1.36; 95 % CI 1.30–1.42), and mortality (RR 5.14; 95 % CI 4.97–5.33) compared with the group without risk. In addition, hospitalizations in the risk group are on average 18 % longer (15.36 days vs. 13.00 days) and 19 % more expensive (12 371 € vs. 10 410 €). Expected hospitalization costs in the risk group are four times greater than in the group without risk (4115 € vs. 1017 €). Conclusions The risk group is vulnerable to COVID-19 and requires additional resources in the German hospital sector. This results in a need for further protective measures. Further studies are needed to evaluate the impact of different viral variants, active and passive immunizations, and therapies on clinical COVID-19 courses and their costs. Article published online: 13 March 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zellkulturbasierte Influenzaimpfstoffe: eine effektive Impfstoffoption für unter 60-Jährige

Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany

Cost-of-illness comparison between clinical judgment and molecular point-of-care testing for influenza-like illness patients in Germany

Impfverhalten von Klinikpersonal verstehen – Ergebnisse der OKaPII-Studie 2023

Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany

Innovations in cell culture-based influenza vaccine manufacturing - from static cultures to high cell density cultivations

Coronaimpfung unter Immunsuppression

A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States

Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons

Out of focus but still relevant? Influenza-related resource utilization and vaccination coverage gaps in adults below 60 years of age with underlying conditions: an analysis of 2016–2024 real-world data in Germany

Cost-effectiveness of cell-based influenza vaccine in France

Thinking beyond Vaccination: Promising Add-On Strategies to Active Immunization and Vaccination in Pandemics-A Mini-Review

Identification and in vivo Efficacy Assessment of Approved Orally Bioavailable Human Host Protein-Targeting Drugs With Broad Anti-influenza A Activity

Allergen-Immuntherapie gegen seltenere Allergene

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Klinische Verläufe und Kosten für Hospitalisierungen von COVID-19-Patienten mit potenziell eingeschränktem Immunsystem in Deutschland

[Vaccination in old age: an overview]

The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses

Opportunities and challenges for T cell-based influenza vaccines

A pilot study using a novel pyrotechnically driven prototype applicator for epidermal powder immunization in piglets

A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019–2020 Influenza Season in the United States